Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 3/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13202304 | 1.00 | TRPV1 (0.55) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2967704 | 1.00 | TRPV1 (0.55) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2978208 | 0.96 | TRPV1 (0.58) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2978204 | 0.96 | TRPV1 (0.58) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2969514 | 0.93 | SIGMAR1 (0.52) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2969518 | 0.93 | SIGMAR1 (0.52) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2962196 | 0.92 | TRPV1 (0.62) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2962194 | 0.92 | TRPV1 (0.62) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL13202234 | 0.91 | TRPV1 (0.55) | TRPV1SIGMAR1TDP1ALDH1A1GAA | |
| SCHEMBL2977052 | 0.91 | EPHX2 (0.52) | TRPV1SIGMAR1TDP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | claimed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1884510-A1 | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884510-A1 | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | TRPV1 10/4885SIGMAR1 84/4885TDP1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.